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Abstract 
We undertook a meta-analysis of six Crohn's disease genome-wide association studies (GWAS) comprising 
6,333 affected individuals (cases) and 15,056 controls and followed up the top association signals in 15,694 
cases, 14,026 controls and 414 parent-offspring trios. We identified 30 new susceptibility loci meeting genome-
wide significance (P < 5 × 10-8). A series of in silico analyses highlighted particular genes within these loci and, 
together with manual curation, implicated functionally interesting candidate genes including SMAD3, ERAP2, 
IL10, IL2RA, TYK2, FUT2, DNMT3A, DENND1B, BACH2 and TAGAP. Combined with previously confirmed 
loci, these results identify 71 distinct loci with genome-wide significant evidence for association with Crohn's 
disease. 
 
Crohn's disease (MIM#266600) results from the interaction of environmental factors, including intestinal 
microbiota, with host immune mechanisms in genetically susceptible individuals. Along with ulcerative colitis, it 
is one of the main subphenotypes of inflammatory bowel disease (IBD). Genome-wide association studies 
(GWAS) have highlighted key pathogenic mechanisms in Crohn's disease, including autophagy and Th17 
pathways. A meta-analysis of these early scans implicated 32 susceptibility loci but only accounted for 20% of 
the genetic contribution to disease risk, suggesting that more loci await discovery1. Recognizing that an 
increased sample size would be required to detect these, we expanded the International IBD Genetics 
Consortium (IIBDGC), approximately doubling the discovery panel size in comparison with the first meta-
analysis. 
The discovery panel for the current study comprised 6,333 individuals with Crohn's disease (cases) and 15,056 
controls, all of European descent, with data derived from six index GWAS studies (for overview, see 
Supplementary Table 1)2-6. Imputation using Hap Map3 reference data allowed us to test for association at 
953,241 autosomal SNPs. Our discovery panel had 80% power to detect variants conferring odds ratios >1.18 at 
the genome-wide significance level of P < 5 × 10-8, assuming a minor allele frequency of ≥20% in healthy 
controls. Underthe same conditions, the sample size of our original meta-analysis had only 11% power1. 
A quantile-quantile plot of the primary meta-statistic using single-SNP z-scores combined across all sample sets, 
showed a marked excess of significant associations (Supplementary Fig. 1). A total of 2,024 SNPs within 107 
distinct genomic loci, including all previously defined significant hits from our earlier meta-analysis (Table 1), 
demonstrated association with P < 10-5. A Manhattan plot is shown in Supplementary Figure 2. We followed 
up 51 of the regions, representing new loci associated at P < 5 × 10-6, by genotyping the most significant SNPs in 
an independent panel of 15,694 Crohn's disease cases, 14,026 controls and 414 parent-offspring trios (Table 2 
and Supplementary Table 2). 
Variants within 30 distinct new loci met a genome-wide significance threshold of P < 5 × 10-8 for association 
with Crohn's disease in the combined discovery plus replication panel, with at least nominal association in the 
replication panel (Table 2). Two additional loci, encompassing CARD9 and IL18RAP, had previously been 
reported as associated with Crohn's disease in a candidate gene study7 and were here both replicated and 
confirmed at P < 5 × 10-8. Another five loci were identified at genome-wide significance in GWAS published 
subsequent to our replication experiment being designed. One, the PUT2 locus, was found in a recent adult 
Crohn's disease GWAS6. Four more (in ZMIZ1 and in IL27 at 16p11, 19q13 and 22q12) were identified in a 
pediatric IBD population5; these identifications were replicated here in our current sample set. Two further loci 
had produced suggestive evidence of association with replication in our earlier study1. Here, these loci clearly 
exceeded the genome-wide significance threshold in the meta-analysis alone and, given the previous replication 
evidence, were not followed up further. Thus, cumulatively, 39 loci can now be added to the 32 confirmed 
Crohn's disease susceptibility loci identified at the time of our original meta-analysis1. We did not observe 
statistically significant heterogeneity of the odds ratios (Breslow Day test P < 0.05 after Bonferroni correction; 
Supplementary Table 3) between the panels from our 15 different countries (Supplementary Tables 1 and 2) 
for any of the 71 loci, nor did we observe any evidence of interaction between the associated loci 
(Supplementary Fig. 3). 
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Table 1 Association results and in silico analyses for 32 previously confirmed Crohn's disease risk loci 












genes of interest 
rs11209026 1p31 67.13-67.54 G 0.932 1.00 × 10-64 2.66 (2.36-3.00) UC, AS, Ps, PBC, GC, 
BD 
IL23R 
rs2476601 1p13 113.66-114.42 G 0.907 4.47 × 10-9 1.26 (1.17-1.37) TlDa, RA, SLE, Ps, 
Vitiligoa, AITD 
PTPN22 
rs4656940 1q23 158.96-159.20 A 0.801 6.17 × 10-7 1.15 (1.09-1.21) SLE, RA CD244, ITLN1 
rs7517810 1q24 170.92-171.21 T 0.246 1.51 × 10-15 1.22 (1.16-1.28) HepC, SLE, SSc, T2D TNFSF18, TNFSF4, 
FASLG 
rs7554511 1q32 199.11-199.32 C 0.726 1.58 × 10-7 1.14 (1.08-1.19) UC, celiac, MS C1orf106, KIF21B 
rs3792109 2q37 233.81-234.23 A 0.529 6.76 × 10-41 1.34 (1.29-1.40) UC ATG16L1 
rs3197999 3p21 48.16-51.73 A 0.297 6.17 × 10-17 1.22 (1.16-1.27) UC MST1, GPX1, BSN 
rs11742570 5p13 39.88-41.00 C 0.606 7.08 × 10-36 1.33 (1.27-1.39) MS PTGER4 




rs7714584 5q33 150.01-150.38 G 0.088 7.76 × 10-19 1.37 (1.28-1.47) TB IRGM 
rs6556412 5q33 158.43-158.88 A 0.332 5.37 × 10-14 1.18 (1.13-1.24) Ps, SLE, malaria, 
asthma 
IL12B 
rs6908425 6p22 20.60-21.25 C 0.784 1.41 × 10-8 1.17 (1.11-1.23) T2D, Ps, UC CDKAL1 
rs1799964 6p21 31.49-32.98 C 0.209 3.98 × 10-11 1.19 (1.13-1.25) Multiple including UC LTA, HLA-DQA2, TNF, 
LST1, LTB 
rs6568421 6q21 106.50-106.67 G 0.301 4.37 × 10-8 1.13 (1.07-1.18)b SLE, RA PRDM1 
rs415890 6q27 167.26-167.47 C 0.522 2.51 × 10-12 1.17 (1.12-1.22) RA, Graves CCR6 
rs1456896 7p12 50.22-50.34 T 0.69 1.20 × 10-8 1.14 (1.09-1.20) AD, SLE, MCV, ALL IKZF1, ZPBP, FIGNL1 
rs4871611 8q24 126.54-126.65 A 0.609 1.51 × 10-12 1.17 (1.12-1.23)   
rs10758669 9p24 4.93-5.29 C 0.349 1.00 × 10-13 1.18 (1.13-1.23) UC, MPD JAK2 
rs3810936 9q32 116.47-116.74 C 0.682 1.00 × 10-15 1.21 (1.15-1.27) UC, leprosy, SpA TNFSF15, TNFSF8 
rs12242110 10ρ11 35.22-35.94 G 0.315 1.10 × 10-9 1.15 (1.10-1.20) UC CREM 
rs10761659 10q21 63.97-64.43 G 0.538 4.37 × 10-22 1.23 (1.18-1.29) BC ZNF365 
rs4409764 10q24 101.26-101.33 T 0.492 2.29 × 10-20 1.22 (1.17-1.27) UC NKX2-3 
rs7927997 11q13 75.70-76.04 T 0.389 5.62 × 10-13 1.17 (1.12-1.22) Atopya C11orf30 
rs11564258 12q12 38.42-39.31 A 0.025 6.17 × 10-21 1.74 (1.55-1.95) PD, leprosy MUC19, LRRK2 
rs3764147 13q14 43.13-43.54 G 0.245 1.41 × 10-10 1.17 (1.12-1.23) Leprosy C13orf31 
rs2076756 16q12 49.02-49.41 G 0.26 3.98 × 10-69 1.53 (1.46-1.60) Leprosy, atopy, Blau, 
GvHD 
N0D2 
rs2872507 17q21 34.62-35.51 A 0.458 1.51 × 10-9 1.14 (1.09-1.19) Asthma, UC, PBC, 
T1D, RA, WBC 
GSMDL, ZPBP2, 
ORMDL3, IKZF3 
rs11871801 17q21 37.57-38.25 A 0.756 2.51 × 10-8 1.15 (1.10-1.21) MSa, obesity, HIES MLX, STAT3 
rs1893217 18p11 12.73-12.92 G 0.153 1.29 × 10-14 1.25 (1.18-1.32) TlDa, celiac PTPN2 
rs740495 19p13 1.04-1.13 G 0.247 8.13 × 10-12 1.16 (1.10-1.21)  GPX4, SBN02 
rs1736020 21q21 15.62-15.77 C 0.579 9.33 × 10-12 1.16 (1.11-1.21) UC  
rs2838519 21q22 44.41-44.52 G 0.391 2.09 × 10-14 1.18 (1.13-1.23) Celiac, UC ICOSLG 
The table reports new data for loci confirmed in the earlier meta-analysis1. Left-right association boundaries are given for each index SNP 
(NCBI's dbSNP build vl30; see Online Methods). Associations with other relevant traits were identified by a literature search using the US 
National Institutes of Health catalog of genome-wide association studies and the HUGE database (version 1.4)43,44. Candidate genes of 
interest are listed. Those in bold were highlighted by in silico analyses (GRAIL connectivity, presence of an eQTL effect with LOD ≥ 5.0 or 
implicated coding SNP; see main text and Supplementary Table 6 for more details). Loci tagged by rs4656940 and rs7554511 previously 
replicated strongly (at 0.00048 and 2.3 × 10-6 replicated previously, respectively1) and still pass genome-wide significance on combined 
analysis. UC, ulcerative colitis; AS, ankylosing spondylitis; Ps, psoriasis; PBC, primary biliary cirrhosis; T1D, type 1 diabetes; RA, 
rheumatoid arthritis; SLE, systemic lupus erythematosus; T2D, type 2 diabetes; MS, multiple sclerosis; AD, Alzheimer's disease; MCV, 
mean corpuscular volume; ALL, acute lymphocytic leukemia; SpA, spondyloarthritis; PD, Parkinson's disease; AITD, autoimmune thyroid 
disease; BC, breast cancer; BD, Behcet's disease; GC, gastric cancer; HepC, hepatitis C susceptibility; SSc, systemic sclerosis; MPD, 
myeloproliterative disease; TB, tuberculosis; GvHD, graft versus host disease; WBC, white blood cell count; HIES, hyper immunoglobulin E 
syndrome.  
aAssociation in the opposite direction in different traits.  
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1p36 7.66-7.89 A 0.19 2.69 × 10-10 1.40 × 10-2 7.10 × 10-9 1.05 (1.01-1.10) Celiac VAMP3 
1q22 153.24-154.39 A 0.25 1.29 × 10-9 2.70 × 10-5 2.30 × 10-13 1.13 (1.06-1.19)a T2D, asthma, PD SCAMP3, MUC1 
1q31 195.58-196.21 G 0.302 4.90 × 10-9 1.60 × 10-2 8.70 × 10-9 1.04 (1.00-1.09) Asthma DENND1B 
lq32 204.87-205.10 T 0.157 8.32 × 10-9 1.50 × 10-7 1.60 × 10-14 1.12 (1.07-1.17) T1D, UC, SLE, 
BD, HepC 
ILW, IL19 
2p23 25.30-25.46 G 0.326 1.41 × 10-8 5.90 × 10-4 8.50 × 10-10 1.06 (1.03-1.10)  DNMT3A 
2p23 27.24-27.71 T 0.418 1.10 × 10-4 3.30 × 10-8 4.70 × 10-11 1.15 (1.10-1.21) CRP, glucose, TGs GCKR 
2p21 43.30-43.80 T 0.129 7.70 × 10-8 2.90 × 10-8 1.60 × 10-14 1.14 (1.09-1.20)a T2D, PC THADA 
2p16b 60.77-61.74 T 0.42 6.61 × 10-9 N/A N/A 1.14 (1.09-1.19) RA, UC, celiac C2orf74, REL 





2q33 197.85-198.67 A 0.473 1.82 × 10-7 1.60 × 10-3 3.50 × 10-9 1.06 (1.02-1.11) CAD PLCL1 
2q37 230.76-230.94 T 0.187 4.57 × 10-9 7.40 × 10-6 3.10 × 10-13 1.12 (1.07-1.18) CLL SP140 
3p24 18.58-18.86 A 0.322 8.20 × 10-7 1.00 × 10-3 6.70 × 10-9 1.08 (1.03-1.13)   
5q13 72.49-72.62 A 0.600 2.00 × 10-6 6.40 × 10-7 5.90 × 10-12 1.12 (1.07-1.17)   
5q15 96.11-96.45 C 0.409 4.47 × 10-11 2.00 × 10-3 1.10 × 10-10 1.05 (1.02-1.09) AS, PD, T1D, PET ERAP2, LRAP 
5q31 141.39-141.62 C 0.796 1.10 × 10-9 4.20 × 10-3 2.00 × 10-9 1.06 (1.02-1.11)  NDFIP1 
5q35 173.15-173.47 T 0.571 5.25 × 10-8 3.30 × 10-6 2.50 × 10-12 1.08 (1.04-1.12)  CPEB4 
6p25 3.35-3.41 T 0.639 6.16 × 10-7 3.10 × 10-4 6.70 × 10-9 1.10 (1.05-1.16)   
6q15 90.86-91.14 G 0.658 3.63 × 10-6 1.40 × 10-4 5.10 × 10-9 1.07 (1.03-1.11) T1D, celiac BACH2 
6q25 159.26-159.46 G 0.393 1.41 × 10-7 2.40 × 10-5 2.30 × 10-11 1.10 (1.05-1.14) RA, celiac, T1Dd TAGAP 
8q24 129.56-129.67 T 0.865 2.29 × 10-6 2.40 × 10-13 3.90 × 10-18 1.23 (1.17-1.30)   
9q34c 138.27-138.54 T 0.411 4.37 × 10-19 1.50 × 10-19 1.30 × 10-6 1.18 (1.13-1.22) UC, AS CARD9, 
SNAPC4 
10p15 6.07-6.21 C 0.852 8.51 × 10-6 5.20 × 10-5 2.90 × 10-9 1.11 (1.05-1.16) MS, T1D, vitiligo, 
RA, AA, asthma, 
AITD 
IL2RA 
10q21 59.50-59.81 C 0.774 1.41 × 10-7 1.10 × 10-10 9.10 × 10-17 1.19 (1.13-1.25) AD UBE2D1 
10q22e 80.67-80.77 G 0.669 2.00 × 10-10 7.30 × 10-22 1.10 × 10-30 1.19 (1.15-1.23) Celiac, MS, 
vitiligo, ESC 
ZMIZ1 
11q12 61.28-61.44 C 0.341 7.24 × 10
-8
 1.70 × 10-5 2.30 × 10-11 1.08 (1.04-1.12) CAD, dyslipidemia FADS1 
11q13 63.58-64.05 A 0.626 3.38 × 10-7 3.50 × 10-4 6.00 × 10-10 1.10 (1.05-1.16) AA PRDX5, ESRRA 
13q14 41.72-42.00 G 0.346 2.00 × 10-6 5.70 × 10-5 4.90 × 10-10 1.10 (1.05-1.15) BMD, RA TNFSF11 
14q24 68.23-68.39 G 0.584 2.00 × 10-7 4.50 × 10-5 1.60 × 10-10 1.07 (1.11-1.04)a Celiac, T1D ZFP36L1 
14q35 87.28-87.71 T 0.119 1.29 × 10-8 5.90 × 10-11 4.20 × 10-18 1.23 (1.16-1.31)a  GALC, GPR65 
15q22 65.20-65.27 T 0.233 1.41 × 10-13 2.00 × 10-8 2.70 × 10-19 1.12 (1.07-1.16) CAD, T2D SMAD3 
16p11e 28.20-28.94 G 0.386 1.10 × 10-10 1.20 × 10-3 1.50 × 10-11 1.07 (1.03-1.12) T1D, obesity, 
asthma, CRC, 




17q12b 29.51-29.70 A 0.723 1.70 × 10-13 N/A N/A 1.20 (1.14-1.26) HIV resistance CCL2, CCL7 




19q13e 38.42-38.47 T 0.612 2.69 × 10-7 2.00 × 10-3 8.70 × 10-9 1.06 (1.02-1.11)   
19q13e 53.78-53.97 A 0.487 8.60 × 10-10 5.20 × 10-5 7.40 × 10-12 1.07 (1.04-1.11) B12, norovirus, HP FUT2, RASIP1 
20q13 61.65-61.95 G 0.709 2.51 × 10-12 4.60 × 10-5 2.70 × 10-15 1.12 (1.06-1.18) Glioma RTEL1, 
TNFRSF6B, 
SLC2A4RG 
22q11 20.14-20.39 T 0.203 6.31 × 10-13 2.30 × 10-6 4.80 × 10-16 1.10 (1.06-1.15) RA, celiac, SLE, 
MCV 
YDJC 
22q12e 28.23-29.00 C 0.471 5.70 × 10-9 8.30 × 10-5 7.30 × 10-12 1.08 (1.04-1.13) IBD, T1D MTMR3 
22q13 38.00-38.14 C 0.830 1.70 × 10-10 9.50 × 10-18 1.10 × 10-26 1.23 (1.17-1.29)  MAP3K7IP1 
The table lists Crohn's disease susceptibility loci newly identified since the first meta-analysis1 with P< 5 × 10-8 in the combined analysis 
(discovery plus replication sample) and P < 0.05 in the replication stage. Seven of these loci have previously been reported (see below). 
Column headings and abbreviations are as described in Table 1. Additional abbreviations are as follows: CRC, colorectal cancer; CRP, C-
reactive protein; TGs, triglycerides; PC, prostate cancer; HSV, human simplex virus; CAD, coronary artery disease; CLL, chronic 
lymphocytic leukemia; BMD, bone mineral density; B12, serum vitamin B12 levels; HP, Helicobacter pylori; AA, alopecia areata. 
aLoci with more than one independent association. bLoci that previously showed suggestive association and replication1 but not at genome-
wide significance. cIL18RAP and CARD9 associations were reported7, but not previously at genome-wide significance, dAssociation in the 
opposite direction in different traits. eLoci previously reported at genome-wide significance in GWAS published subsequent to design of the 
current replication experiment5,6. 
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Regional association plots of all 71 susceptibility loci, includingthe underlying genes, are shown in detail in 
Supplementary Figure 4, and complete genotype data, including odds ratios and allele frequencies, are shown 
in Supplementary Tables 3 and 4. Five loci showed evidence for more than one independently associated 
variant (Table 2). Although six of the 30 newly discovered regions contain just a single gene, which is thereby 
strongly implicated in Crohn's disease pathogenesis (for example, SMAD3, NDFIP1 and BACH2), 22 of these 
regions include more than one gene within the associated interval (Table 2). We thus applied additional in silico 
analyses to refine the list of functional candidate genes further. These analyses were (i) interrogation of a 
publicly available expression quantitative trait loci (eQTL) database8, which identified genes for which 
expression correlates with genotype at our most associated SNP (Supplementary Note), (ii) use of 1000 
Genomes Project Pilot sequence data and HapMap3 data to identify genes containing non-synonymous variants 
in strong linkage disequilibrium (r2 > 0.5) with the focal SNP within each region (for details on coding SNPs, see 
Supplementary Table 5) and (iii) use of GRAIL9 to identify non-random and evidence-based connectivity 
between the genes in the 71 confirmed Crohn's disease loci. Specifically, GRAIL evaluates each gene within a 
Crohn's disease-associated locus for non-random correlation with genes in the other 70 loci through word-usage 
in PubMed abstracts related to the gene (Fig. 1). 
 
Figure 1 Gene relationships across implicated loci (GRAIL) pathway analysis. Links between genes at 23 of 71 
Crohn's disease-associated oci which scored P < 0.01 using GRAIL. Specifically, of the 71 Crohn's disease-associated 
SNPs, 69 are in linkage disequilibrium intervals containing or within 50 kb of at least one gene. In total, there were 355 genes implicated by 
proximity to these 69 SNPs. Each observed association was scored with GRAIL, which takes each gene mapping within Crohn's disease-
associated intervals and evaluates for each whether it is non-randomly linked to the other genes through word usage in PubMed abstracts. 
The 23 SNPs shown in the outer circle are significant at P < 0.01, indicating that the regions which they tag contain genes which are more 
significantly linked to genes in the other 68 regions than expected by chance at that level. The lines between genes represent individually 
significant connections that contribute to the positive signal, with the thickness of the lines being inversely proportional to the probability 
that a literature-based connection would be seen by chance. To accurately assess the statistical significance of this set of connections, we 
conducted simulations in which we selected 1,000 sets of 69 SNPs implicating in total 355 genes ± 18 genes (5%) (selecting the SNPs 
randomly and using rejection sampling, only taking lists that implicated the same number of genes). Each of those 1,000 sets was scored with 
GRAIL. The mean number of P < 0.01 hits in a simulated list was 0.91, with a range in the 1,000 sets from 0 to 11, suggesting that the 
likelihood of observing 23 hits with P < 0.01 is far less than 0.1%. 
 
 
Summary results of these analyses are shown in the rightmost column of Table 1 and Table 2 and in 
Supplementary Table 6. Highlighted genes are described briefly in Box 1, as are genes that constitute 
particularly noteworthy candidates from intervals containing one or few genes. Although we believe that these 
evidence-based approaches are helpful in identifying likely functional candidates, in some instances, the 
different techniques highlight different genes. This reflects uncertainty as to which genes are causal and 
emphasizes the need for functional studies. 
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We identified 30 new signals here beyond those described in the earlier meta-analysis1 and other subsequent 
publications. The discovery of these new associations was driven primarily by increased power arising from the 
expanded sample size rather than improved imputation, as more than two-thirds of the newly discovered loci 
have good proxies (r2 > 0.8) on both generation arrays used in the earlier studies (Illumina 300K and Affymetrix 
500K). Extending this argument beyond the current analysis, it seems likely that many more loci of modest 
effect size still await discovery. 
For many of the loci, associations have been reported previously in other complex diseases, comprising mostly 
chronic inflammatory disorders (Tables 1 and 2). Such diseases can cluster both within families and within 
individuals, reflecting shared genetic risk factors. For example, IBD and ankylosing spondylitis can co-segregate 
and both are associated with IL23R (refs. 2,10) and TNFSF15 (refs. 11,12). The IL10 locus was previously 
associated with ulcerative colitis13 and was identified as a new Crohn's disease risk locus here. Thus, IL10 is a 
generic IBD locus, which is a functionally intuitive finding of potential therapeutic significance. 
For loci previously associated with other inflammatory diseases, the direction of effect in Crohn's disease is 
usually the same; however, in five instances, the risk allele for one disease appears to be protective in another 
disease (see arrow symbol in the reported association column in Tables 1 and 2). In most such instances, 
functional annotation suggests modulation of T cells and other immune pathways. Indeed, GRAIL highlights a 
number of such genes. These inverse associations may reflect overlap in the pathways by which the host 
regulates effector functions in defense and regulatory functions in self tolerance. This is a delicate balance and, 
in the face of competing requirements, selection pressures may have conferred an advantage for divergent alleles 
in a cell- and environment-dependent manner. 
The associated SNP rs281379 at 19ql3, also recently identified in another study6, is highly correlated (r2 > 0.80) 
with a common nonsense variant (rs601338, also known as c.428G>A or p.Trp142X) at FUT2. This is 
classically referred to as the non-secretor variant, as individuals homozygous for this null allele do not secrete 
blood group antigens at epithelial surfaces. Recently, non-secretors were identified as having near-complete 
protection from symptomatic GII.4 norovirus infection14, and the same null allele is identified here as a risk 
factor for Crohn's disease. This suggests one potential elusive link between infection and immune-mediated 
disease. 
In contrast to the implication of coding variation in FUT2, our previous data showed that most Crohn's disease-
associated SNPs were not in linkage disequilibrium with coding polymorphisms1, suggesting that regulatory 
effects are likely to be a more common mechanism of disease susceptibility. Providing further direct evidence 
for this, we here identified a number of new eQTL effects (Table 2 and Supplementary Note), including 
CARD9 (log10 odds score (LOD) = 12.4), ERAP2 (LOD = 47.2) and TNFSF11 (also known as RANKL) (LOD = 
5.9). The latter maps adjacent to but outside the associated recombination interval, suggesting another potential 
long-range cis-regulatory effect as previously described for PTGER4 in Crohn's disease4. RANKL has 
pleiotropic immunological effects and also stimulates osteoclast activity. This finding may be relevant to the 
osteoporosis clinically associated with Crohn's disease. 
Given the importance of regulatory effects, it is notable that variants within the gene encoding a key mediator of 
epigenetic regulation, DNMT3A (the DNA methyltransferase 3A gene), should be associated with Crohn's 
disease. By inducing transcriptional silencing, DNMT3A is known to play an important role in 
immunoregulation. For example, DNMT3A methylates IL-4 and IFN-γ promoters following T-cell-receptor 
stimulation, hence regulating T-cell polarization15, and induces dynamic regulation of TNF-α transcription 
following lipopolysaccharide exposure in leukocytes16. Genetically determined alterations in DNMT3A activity 
could thus have far-reaching effects. 
The 32 loci described up until 2008 explained approximately 20% of Crohn's disease heritability Adding the 39 
loci described since that time increases the proportion of heritability explained to only 23.2%. This pattern of 
common alleles, explaining a logarithmically decreasing fraction of heritability (Fig. 2), is consistent with a 
recent model of effect size distribution17, which predicted (based on the previous Crohn's-disease meta-analysis) 
that our current sample size would likely identify 48 new loci. Furthermore, it is likely that more high-frequency 
Crohn's disease risk alleles of even smaller effect size remain unidentified: the same model predicts that 140 loci 
would be identified by a sample size of 50,000, but these loci would explain only a few more percent of Crohn's 
disease heritability. It is clear, therefore, that larger GWAS alone will not explain all of the missing heritability 
in Crohn's disease. 
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Box 1  Noteworthy genes within loci newly implicated in Crohn's disease pathogenesis 
Although we highlight these as interesting genes, we do not yet have data to confirm causality. 
■ VAMP3 (1p36) encodes vesicle-associated membrane protein 3. Following bacterial stimulation of TNF-α 
production within macrophages, VAMP3 interacts with SNARE proteins first on the trans-Golgi network, where TNF-
α is taken up, and then on the cell membrane, where TNF-α is released19. VAMP3 also plays a role in cell migration 
and adhesion by trafficking molecules such as βl integrin to the cell surface, and it has been implicated in autophagy20. 
■ MUC1-SCAMP3 (1q22). MUC1 encodes a key constituent of mucus, which is the physical barrier that protects the 
intestinal epithelium from gut bacteria. MUC1 overexpression and hypoglycosylation have been reported in IBD21, and 
Mucl knockdown mice exhibit increased small intestinal damage after C. jejuni infection22. Secretory carrier 
membrane protein 3 (encoded by SCAMP3) regulates EGFR trafficking within endosomal membranes23. It is 
manipulated by intracellular salmonellae to acquire nutrients and influence host immune responses24. 
■ DENND1B (1q31) has recently been associated with asthma25 and is expressed in dendritic and natural killer cells. 
DENN-containing proteins influence MAP-kinase signaling pathways and DENND1B, in particular, has been 
predicted to interact with TNFR1. 
■ IL10 (1q32). Association with Crohn's disease follows its recent implication in ulcerative colitis13 and the reporting 
of mutations in the IL10 receptors in extreme Crohn's disease in infancy26. Known to inhibit synthesis of pro-
inflammatory cytokines within macrophages and Thl cells, IL-10 also suppresses antigen-presenting cell activity. 
Knockdown of IL-10 in mice presents one of the best animal models of IBD. 
■ DNMT3A (2p23). DNA methyltransferase 3A is one of three key methyltransferase genes in humans, effecting 
epigenetic regulation of gene transcription by methylating cytosine residues within CpG islands. Among many other 
roles, this protein is known to determine dynamic regulation of both adaptive and innate immune mechanisms15,16. 
■ GCKR (2p23) encodes an inhibitor of glucokinase, with the focal SNPs at this locus also correlating with both 
fibrinogen and CRP levels27. 
■ THADA (2p21) is expressed in the small intestine and appears to encode a death receptor-interacting protein, 
suggesting an apoptotic function28. 
■ ERAP2 (5q15). Regulated by NF-κB, this gene encodes one of two human endoplasmic reticulum aminopeptidases, 
which work in concert to trim peptides for presentation on MHC class 1 and hence critically affect antigen presentation 
to T cells29. Ankylosing spondylitis is associated with this locus, but with a different pattern of associated variants30. 
Given the close clinical relationship between Crohn's disease and ankylosing spondylitis, and the strong association of 
HLA-B27 with the latter but not with the former, the divergent association of these closely related molecules is 
intriguing and will refocus interest on the MHC class 1 associations in Crohn's disease. 
■ NDFIP1 (5q31). Nedd4-family interacting protein 1 is a membrane protein involved in maintenance of the Golgi 
complex31. It is important for protein trafficking through exosomes and may play a role in rapid sequestration and 
removal of proteins during stress32. 
■ CPEB4 (5q35) encodes a regulator of protein translation and cell division and is a transcriptional target of RORγt. 
Mouse work suggests that the product of CPEB4 is the effector by which RORγt (a key determinant of Thl7 cell 
differentiation) inhibits proliferation of thymocytes33. 
■ TAGAP (6q25). T-cell activation GTPase-activating protein, associated with multiple autoimmune diseases, was 
originally identified through its involvement in human T-cell activation and co-regulation with IL-2 (ref. 24). 
■ IL2RA (10p15) encodes part of the IL-2 receptor complex, thus mediating IL-2 signaling in host defense and 
regulating response to autoantigens by Tregs. The associated variants correlate with differential expression of IL2RA 
(CD25) on CD4+ naive and memory T cells35 possibly affecting Foxp3+ Treg homeostasis36. 
■ FADS2 (11q12). Fatty acid desaturase 2 is predominantly located in the endoplasmic reticulum. Fads2 knockdown 
mice develop duodenal and ileocecal ulceration37. 
■ TNFSF11 (13q14), also called RANKL (receptor activator of nuclear factor kappa B) and ODF (osteoclast 
differentiation factor), encodes a member of the TNF cytokine family. RANKL stimulation of dendritic cells leads to 
proliferation of naive T cells and inducible Tregs38. It also regulates osteoclast activity and bone loss. Previous studies 
have demonstrated increased plasma levels in Crohn's disease39. 
■ SMAD3 (15q22). Phosphorylated following TGF-β signaling through its receptor, the SMAD3 protein complexes 
with SMAD4 and is then translocated to the nucleus to modulate target gene expression. SMAD3 plays a key role in 
the TGF-β-mediated induction of Foxp3+ regulatory T cells40, with SMAD3 deficiency reciprocally enhancing Thl7. 
Reduced SMAD3 phosphorylation has been observed in IBD and may impair the immunosuppressive effect of TGF-β. 
■ TYK2 (19p13) encodes tyrosine kinase 2, a member of the JAK-signal transduction family. It is involved in cytokine 
signaling by IFN-γ, IL-12 and IL-23 among others, hence affecting Thl and Thl7 lineage development. TYK2 also 
plays an important role in TLR-mediated responses in dendritic cells, including IL-12 and IL-23 production, and TYK2 
mutations predispose to opportunistic infection41. 
■ FUT2 (19q13) encodes α-(l,2)fucosyltransferase, which regulates expression of the Lewis AB0 (H) histo-blood 
group of antigens on the surface of epithelial cells and in body fluids. It is strongly associated with Norovirus infection, 
as well as with with Helicobacter pylori infection and serum vitamin B12 levels14,42. 
 
Published in: Nature Genetics (2010) 
Status: Postprint (Author’s version) 
 
 
One key shortcoming of our current model of heritability explained by these loci is a direct consequence of the 
extent to which GWAS tag SNPs are often imperfect proxies for causal alleles and thus substantially 
underestimate the true attributable risk. For example, the best tag SNP at the NOD2 locus in our meta-analysis 
appears to explain just 0.8% of genetic variance, whereas the three NOD2 coding mutations themselves account 
for 5%. If an analogous situation applies to even a small fraction of the other 70 Crohn's disease susceptibility 
loci, the proportion of overall heritability explained will increase substantially. Indeed, one study of linkage 
disequilibrium between tag SNPs and causal variants in the heritability of human height18 suggests that this 
effect might double the total fraction of heritability explained by GWAS SNPs. Coding variants identified here 
from the 1000 Genomes Project that are in strong linkage disequilibrium with the focal SNPs in several of our 
regions (Supplementary Table 5) thus now require direct assessment in order to explore this possibility. 
 
Figure 2 Cumulative fraction of genetic variance explained by 71 Crohn's disease risk loci. The loci are ordered from 
largest to smallest individual contribution. Black points were identified pre-GWAS, green points were dentified in the first generation 
GWAS, blue points were identified in an earlier meta-analysis, and cyan points were identified in this analysis. The inset shows a logarithmic 
fit to these data extrapolated to an extreme scenario where 20,000 independent common alleles are associated with disease. Even in this 
situation, less than half of the genetic variance would be explained. This demonstrates that other types of effect (for example, low frequency 
and rare alleles with higher penetrance) must also exist. 
 
 
Other factors will also account for the heritability gap, including uncertain epidemiological estimates of disease 
prevalence and total heritability, as well as our observation that several of the new regions contain more than one 
independent risk allele. The likelihood is that many more such effects will be identified. Indeed, detailed future 
analyses will play a key role in helping us to understand the absolute contribution of common causal alleles, as 
well as in identifying lower frequency variants and rare (even family-specific) mutations. By contrast, our lack of 
evidence for epistasis among the loci described here suggests that non-additive interactions among common risk 
alleles do not play an important role in the genetic architecture of Crohn's disease. 
The current study has approximately doubled the number of confirmed Crohn's disease susceptibility loci. For 
many of these loci, we have identified potentially causal genes, though confirmation of their role must await 
detailed fine mapping, expression and functional studies. Although the alleles detected only modestly affect 
disease risk, they continue to enhance our understanding of the genetic etiology of Crohn's disease. Looking for 
evidence of sub-phenotype associations represents an important future goal for the consortium. Thus, we are 
working toward sharing detailed genotype and clinical data to allow this. In the meantime, extensive 
resequencing, together with large-scale fine mapping exercises using custom array-based technologies, is already 
underway and will further elucidate the pathogenic mechanisms of IBD. 
URLs. Evoker v1.0, http://www.sanger.ac.uk/resources/software/ evoker/. 
 
ONLINE METHODS 
Note: Supplementary information is available on the Nature Genetics website. 
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All study subjects were of European origin. The meta-analysis was based on data from 6,333 Crohns disease 
cases and 15,056 controls derived from six index genome-wide scans from Germany, Cedars-Sinai Medical 
Center (Los Angeles, California, USA)6, the CHOPSTICKS consortium (of early onset cases)5, and the 
NIDDK45, Wellcome Trust Case Control Consortium (WTCCC)46 and Belgian-French4 studies. Details of the 
numbers of cases and controls genotyped in the respective scans and of the genotyping platforms used are given 
in Supplementary Table 1. The methods of ascertainment of the GWAS cohorts, as well as of quality control 
procedures applied, were provided in the aforementioned original publications. The GWAS set from Germany 
has not yet been published but used standard methods of data filtering, removing samples with >1% missing 
genotypes and using PLINK to identify samples with excess allele sharing (hence removing duplicates and 
retaining only one individual from pairs or groups of relatives) and to detect population structure, allowing 
removal of outliers identified by principal components analysis. 
Details of the replication panel of 15,694 cases and 14,026 controls plus 414 parent-affected offspring trios are 
provided in Supplementary Table 2. As with the GWAS subjects, the replication cases were ascertained in 
major IBD centers using standard clinical, endoscopic, radiological and histopathological criteria for diagnosis of 
Crohns disease. Each center supplying cases also supplied its own panel of controls. The controls for the Cedars-
Sinai study were obtained from the Cardiovascular Health Study (CHS), a population-based longitudinal study of 
risk factors for cardiovascular disease and stroke in adults 65 years of age or older, recruited at four field 
centers47. Five thousand two hundred and one individuals were recruited in 1989-1990 from random samples of 
Medicare eligibility lists, followed by an additional 687 individuals recruited in 1992-1993 (total n = 5,888). 
All participating centers received approval from their local and national institutional review boards, and 
informed consent was obtained from all participants. 
Imputation 
GWAS imputation was carried out using BEAGLE48,49 and the HapMap3 reference samples from the CEU, TSI, 
MEX and GJT collections, with the exception of the early onset samples, which were imputed using the MACH 
program and the HapMap2 CEU reference samples. We carried forward a set of 953,242 autosomal markers 
(HapMap3 X-chromosome data were not available) that were polymorphic in at least one GWAS dataset for 
association analysis. 
Test for association 
We used genotype probabilities and empirical variances to summarize the standard 1 degree-of-freedom allele-
based test for association as a z-score within each scan and combined the scores across all six datasets (inversely 
weighted by variance) to produce a single meta-statistic for each SNP. Odds ratios for replicated SNPs were 
estimated jointly from all case-control replication data available. Genomic positions were retrieved from NCBΓs 
dbSNP build vl30. Linkage disequilibrium regions around focal SNPs were defined by extending the region to 
the left for 0.1 cM or until another SNP with P < 10-5 was reached, in which case the process was repeated from 
this SNP. Right-hand boundaries were defined in the same way. 
Notably, the 'belge' and 'cedar2' GWAS collections showed more pronounced inflation than the other six 
collections (Supplementary Fig. 1). Three lines of evidence suggest that population structure in these 
collections is not driving the association at our 71 loci: (i) the principal component analysis-corrected association 
analysis of the belge and cedar2 samples implies that some of the inflation is due to population stratification (the 
belge inflation decreased from 1.2 to 1.15 and the cedar2 decreased from 1.30 to 1.05 after control for the 
principal components). Under the null hypothesis that all association signals were driven by this stratification, 
we would expect a consistent decrease in significance at our 71 loci after correction. By contrast, 28 loci become 
more significant in the belge subset and 37 loci become more significant in the cedar2 subset after correction, 
whereas the P values of the remaining loci did not change significantly. This is especially noteworthy because 
the additional degrees of freedom in the corrected test reduced power on average, and this evidence strongly 
affirms that the signals at these 71 loci are driven by disease association and not by confounding. For nearly all 
SNPs, the change before and after corrections was small (Supplementary Table 3). (ii) The belge and cedar2 
panels only represent 11% of our GWAS sample, making it difficult for them to drive associations in the full 
meta-analysis. We also tested for heterogeneity of odds ratios across all collections and found no significant 
differences after correcting for 71 tests (Supplementary Table 3). (iii) Some of the overall study inflation is due 
to true disease signal because the inflation factor decreases from 1.27 to 1.24 after excluding the known loci 
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(with many more to be identified in the future). 
Replication 
We selected the most significantly associated SNP from each region that was taken forward to replication and 
carried out genotyping according to standard protocols associated with platforms described in Supplementary 
Table 2. Samples with > 10% missing data in any experiment were excluded from further analysis. 
The following additional quality controls were applied to the data before the association analysis: (i) visual 
and/or manual inspection of each cluster plot, that is, the genotype assignment and cluster separation were 
manually checked. For the Sequenom data, we used Evoker v1.0 (see URLs)50 to examine the cluster plots. For 
SNPlex, genotype assignments were verified visually using the GeneMapper 4.0 (Applied Biosystems) software, 
and for TaqMan, we used the SDS v2.3 progam (Applied Biosystems). The aim of examining a cluster plot is 
twofold: to determine whether a given SNP has been genotyped well (in particular, whether clear distinct clusters 
can be identified on the plot that would correspond to the three genotypes) and to determine whether the calling 
algorithm has called the clusters correctly. If both of these requirements were fulfilled, as genotype counts can 
usually be assumed to be sufficiently accurate. If not, any observed disease association of such a SNP may be 
due to incorrect genotype counts, (ii) Call rate (genotype success rate) in each case or control panel greater than 
95%. (iii) Hardy-Weinberg P > 10-4 in each healthy control sample. 
Replication and joint P values were calculated using the weighted z statistic described above. 
Heritability analyses 
We estimated the fraction of additive genetic variance explained using the liability threshold model of Risch51, 
which assumes an additive effect at each locus and which shifts the mean of a normally distributed distribution 
of disease liability for each genotype class. Given the lack of evidence for gene-gene interaction among our 71 
loci, we consider these contributions to be additive. We assumed a prevalence of Crohns disease of 4 per 1,000 
and a total narrow-sense heritability of 50% (ref. 52). Results of this analysis are shown in Figure 2. 
Interaction analyses 
To test for pairwise interactions among the 71 confirmed associated loci, we performed an interaction meta-
analysis using the approach described below. Each of the six scans performed an identical pairwise scan of the 
71 × 70/2 pairs of SNPs in Tables 1,2 using logistic regression in which three terms (dosage of SNP 1, dosage of 
SNP 2 and an additive interaction term) were included. The significance of this interaction terms was represented 
by a directional z-score which was then combined across all six studies using a sample-size-weighted 
combination of z-scores. The overall combined quantile-quantile plot resulting from this analysis showed no 
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